NEW DELHI: Prescription drugs agency Cipla Ltd on Friday reported a 44.9 per cent rise in consolidated revenue after tax at Rs 1,155.37 crore within the second quarter ended September 2023. The corporate had posted a consolidated revenue after tax of Rs 797.41 crore within the July-September quarter final fiscal, Cipla Ltd stated in a regulatory submitting.
Consolidated whole income from the sale of merchandise within the quarter below assessment stood at Rs 6,589.22 crore, up 14.41 per cent, as in opposition to Rs 5,759.28 crore within the year-ago interval.
Its whole bills within the September quarter had been 8.43 per cent greater at Rs 5,260.24 crore as in comparison with Rs 4,851.13 crore within the corresponding interval final fiscal, the corporate stated.
Whole earnings of Cipla within the September quarter was at Rs 6,854.47 crore, up 15.17 per cent.
In the course of the quarter, its income from prescription drugs was at Rs 6,452.54 crore, and from new ventures at Rs 263.77 crore.
Shares of Cipla Ltd had been buying and selling at Rs 1,179.70 on BSE on Friday, up 2.57 per cent from the earlier shut.
Consolidated whole income from the sale of merchandise within the quarter below assessment stood at Rs 6,589.22 crore, up 14.41 per cent, as in opposition to Rs 5,759.28 crore within the year-ago interval.
Its whole bills within the September quarter had been 8.43 per cent greater at Rs 5,260.24 crore as in comparison with Rs 4,851.13 crore within the corresponding interval final fiscal, the corporate stated.
Whole earnings of Cipla within the September quarter was at Rs 6,854.47 crore, up 15.17 per cent.
In the course of the quarter, its income from prescription drugs was at Rs 6,452.54 crore, and from new ventures at Rs 263.77 crore.
Shares of Cipla Ltd had been buying and selling at Rs 1,179.70 on BSE on Friday, up 2.57 per cent from the earlier shut.
